Clinical Research of α-lipoic Acid and Alprostadil Injection Combination Therapy Diabetic Peripheral Neuropathy

Xiang-dong REN

DOI: https://doi.org/10.15912/j.cnki.gocm.2011.35.238

2011-01-01

Abstract:Objective To study the use of alprostadil combined with α-lipoic acid on diabetic peripheral neuropathy(DPN) of the clinical effect.Methods Endocrinology hospital between 2010-2011 with the treatment of Type 2 diabetes have peripheral neuropathy 60 patients in this study.Good control of blood glucose in all patients on the basis of random divided into A,B groups,A group treatment given alprostadil combined α-lipoic acid,B group therapy give vitamin B12.Observed and compared two groups of patients before and after treatment in diabetic peripheral neuropathy symptoms and motor and sensory nerve reached the speed of change.Results After treatment,the joint use of alprostadil in patients with α-lipoic acid treatment efficiency of 90%,while patients treated with vitamin B12 treatment rate was 73.33%,the use of alprostadil combined α-lipoic acid treatment in patients treated better than simple patients treated with vitamin B12.Kay,when combined with α-lipoic acid-treated patients before and after treatment after treatment of motor and sensory nerve spread to increase the speed of change is better than simply the treatment of patients with vitamin B12.Conclusions Alprostadil combined α-lipoic acid treatment of diabetic peripheral neuropathy can effectively improve the patient's peripheral neuropathy symptoms improve motor nerve conduction velocity(MNCV) and sensory nerve conduction velocity(SNCV),can promote the use of clinical treatment.